Stocks · Health care · Pharmaceutical Preparations

GENELUX Corp

GNLX Clue Score27
United States Fiscal year ends December CIK 0001231457 Results filed 25 Mar 2025

What the insiders did Net selling

Insider
Date
Role
Action
Shares
Price
Amount
Yong Yu
3 Nov 2026
Chief Scientific Officer
Sell
668
$2.01
$1.34K
Thomas Zindrick
3 Nov 2026
President and CEO
Sell
3,089
$2.05
$6.32K
Joseph Cappello
3 Nov 2026
Chief Technical Officer
Sell
668
$2.04
$1.36K
Yong Yu
31 Aug 2026
Chief Scientific Officer
Sell
9,683
$2.75
$26.66K
Thomas Zindrick
31 Aug 2026
President and CEO
Sell
34,463
$2.67
$91.90K
Joseph Cappello
31 Aug 2026
Chief Technical Officer
Sell
10,257
$2.74
$28.11K
Thomas Zindrick
4 Aug 2026
President and CEO
Sell
3,023
$2.95
$8.91K
Joseph Cappello
4 Aug 2026
Chief Technical Officer
Sell
653
$2.95
$1.92K
Yong Yu
4 Aug 2026
Chief Scientific Officer
Sell
653
$2.94
$1.92K
John W Smither
1 Jul 2026
Director
Sell
12,000
$2.91
$34.90K
Ralph Smalling
3 Jun 2026
Head of Regulatory
Sell
192
$2.93
$562.56
Ralph Smalling
11 May 2026
Head of Regulatory
Sell
270
$2.98
$804.49
Thomas Zindrick
11 May 2026
President and CEO
Sell
2,798
$2.94
$8.23K
Joseph Cappello
11 May 2026
Chief Technical Officer
Sell
605
$2.97
$1.80K
Yong Yu
11 May 2026
Chief Scientific Officer
Sell
605
$2.97
$1.80K
Ralph Smalling
25 Mar 2026
Head of Regulatory
Sell
240
$2.51
$602.40
Thomas Zindrick
24 Mar 2026
President and CEO
Sell
3,582
$2.42
$8.67K
Yong Yu
24 Mar 2026
SVP, Clinical Development
Sell
906
$2.42
$2.19K
Joseph Cappello
24 Mar 2026
Chief Technical Officer
Sell
906
$2.42
$2.19K
Ralph Smalling
24 Mar 2026
Head of Regulatory
Sell
345
$2.42
$834.90
Ralph Smalling
5 Dec 2025
Head of Regulatory
Sell
165
$4.69
$773.85
Ralph Smalling
17 Nov 2025
Head of Regulatory
Sell
343
$5.37
$1.84K
Joseph Cappello
17 Nov 2025
Chief Technical Officer
Sell
973
$5.37
$5.22K
Thomas Zindrick
17 Nov 2025
President and CEO
Sell
4,509
$5.37
$24.21K
Yong Yu
17 Nov 2025
SVP, Clinical Development
Sell
973
$5.37
$5.22K

What was left out

Form 4 filings counted 36
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 3
Sales straight out of an exercise 0
Sales at will 25
Transactions with no price 0
Shares from compensation/vesting 1,651,259
History held since 30 Jan 2023